Research And Development
Health
Pharmaceutical

Enzo Biochem

$2.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.16%) Today
+$0.35 (13.73%) After Hours

Why Robinhood?

You can buy or sell Enzo Biochem and other stocks, options, ETFs, and crypto commission-free!

About

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. Read More The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Employees
503
Headquarters
New York, New York
Founded
1976
Market Cap
121.88M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
171.04K
High Today
$2.61
Low Today
$2.52
Open Price
$2.60
Volume
152.44K
52 Week High
$6.89
52 Week Low
$2.32

Collections

Research And Development
Health
Pharmaceutical
Biotechnology
Medical
Technology

News

Seeking Alpha60s

Enzo Biochem +23.5% as holder raises stake, presses strategic review

Enzo Biochem (NYSE:ENZ) is up 23.5% after hours, in relatively light trading so far, after shareholder Roumell Asset Management notes in a filing that it's boosted its stake to 4% and is seeking a review of strategic options.

11
Simply Wall StMar 6

What Kind Of Investor Owns Most Of Enzo Biochem, Inc. (NYSE:ENZ)?

The big shareholder groups in Enzo Biochem, Inc. (NYSE:ENZ) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Enzo Biochem is a smaller company with a market capitalizatio...

132
BusinessWireMar 5

Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 at 8:30 AM E.T.

NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 second quarter results Tuesday, March 12, 2019, at 8:30 AM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. When prompted, use PIN number 2037608. Dial in approximately ten minutes prior to the scheduled teleconference time. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 A...

32

Earnings

-$0.18
-$0.12
-$0.07
-$0.01
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Jun 10, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.